Company profile

FENNEC PHARMACEUTICALS INC.

NASDAQ:FENCBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (1)

AssetStageRevenueTrialsStatus
Sodium Thiosulfateapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (0)

No records yet.

FDA applications (1)

ApplicationTypeApplicantProducts
NDA 212937NDAFENNEC PHARMACEUTICALS INC